The subcutaneous immunoglobulin (scig) global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Subcutaneous Immunoglobulin (SCIG) Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size — The subcutaneous immunoglobulin market size has grown rapidly in recent years. It will grow from $11.19 billion in 2023 to $12.72 billion in 2024 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to the increased prevalence of immunodeficiency disorders, rise in the patient preference for home-based care, enhanced therapeutic efficacy, growth in the awareness and diagnosis rates, growth in the favorable reimbursement policies.
The subcutaneous immunoglobulin market size is expected to see rapid growth in the next few years. It will grow to $21.38 billion in 2028 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to the growing prevalence of neurological disorders, increasing prevalence of autoimmune diseases, rising awareness and acceptance of immunoglobulin therapy, expanding applications in neurology and dermatology, expansion of healthcare facilities. Major trends in the forecast period include advancements in drug delivery systems, increasing demand for home infusion therapies, developments in antibody therapy, Innovations in formulations, and Innovations in SCIG.
Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report
Scope Of Subcutaneous Immunoglobulin (SCIG) MarketThe Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Subcutaneous Immunoglobulin (SCIG) Market Overview
Market Drivers -The increase in the prevalence of secondary immunodeficiency diseases is expected to propel the growth of the subcutaneous immunoglobulin market going forward. Secondary immunodeficiency diseases are conditions with a reduced or compromised immune system caused by sources other than the immune system itself. The prevalence of secondary immunodeficiency diseases is driven by various factors such as aging populations, the use of immunosuppressive treatments, and environmental toxins. Subcutaneous immunoglobulin therapy provides antibodies to help strengthen the weakened immune system, especially in chronic disorders such as HIV or autoimmune diseases, thereby preventing infections and supporting immunological function during treatment. For instance, in October 2023, according to the UK Health Security Agency, a UK-based government agency, reported 3,805 new HIV diagnoses in England in 2022, representing a 22% rise from the previous year. Therefore, the increase in the prevalence of secondary immunodeficiency diseases is driving the growth of the subcutaneous immunoglobulin market.
Market Trends — Major companies operating in the subcutaneous immunoglobulin market are developing subcutaneous human-klhw, a unique formulation containing human immune globulins (Ig) that strengthens the immune system. Subcutaneous human-klhw is used for subcutaneous administration, developed for treating primary immunodeficiency diseases in human body. For instance, in March 2022, Grifols S.A., a Spain-based pharmaceutical company, launched XEMBIFY 20% subcutaneous immunoglobulin (SCIG). It is specifically designed to treat primary immunodeficiency, meeting a significant medical need for people with weakened immune systems. XEMBIFY is a ready-to-use formulation that simplifies the treatment process and increases patient convenience. It is stable at room temperature for up to 24 months, avoiding the need for refrigeration during storage and transportation, which can be extremely useful in a variety of healthcare settings.
The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented —
1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses
Get an inside scoop of the subcutaneous immunoglobulin (scig) market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp
Regional Insights — North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies — Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy’s Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc. , Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc
Table of Contents 1. Executive Summary2. Subcutaneous Immunoglobulin (SCIG) Market Report Structure3. Subcutaneous Immunoglobulin (SCIG) Market Trends And Strategies4. Subcutaneous Immunoglobulin (SCIG) Market — Macro Economic Scenario5. Subcutaneous Immunoglobulin (SCIG) Market Size And Growth…..27. Subcutaneous Immunoglobulin (SCIG) Market Competitor Landscape And Company Profiles28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
